Latest News and Updates

Stay updated on RocRock latest news

2022

RocRock Bio and Risegene Bio have reached a cooperation agreement. They will conduct non - registered clinical research on therapies targeting solid tumors at the Affiliated Hospital of Xuzhou Medical University.
December 8, 2022

On December 8, 2022, RocRock Bio (Shenzhen) Co., Ltd. ("RocRock Bio") and Jiangsu Risegene Bio-tech Research Institute Co., Ltd. entered into a cooperation agreement to conduct non - registered clinical research on therapies targeting solid tumors at the Affiliated Hospital of Xuzhou Medical University.

Learn More
RocRock Bio and Pu Heng Technology Collaborate on a High - throughput Development Platform for CAR-Macrophage Using 3D In Vitro Solid Tumor Models.
November 23 2022

RocRock Bio (Shenzhen) Co., Ltd. ("RocRock Bio") and Suzhou Pu Heng Technology Co., Ltd. ("Pu Heng Technology") have entered into a strategic cooperation agreement. They will leverage the 3D NAC-Organ technology platform to develop a high-throughput in vitro screening system for CAR-Macrophage cells, targeting the acceleration of innovative immunotherapies for solid tumors.

Learn More
The latest research findings on RocRock Bio's Del-M platform have been published on bioRxiv.
May 5, 2022

The RocRock Bio team published an un-peer-reviewed study titled "TME induced TRAIL secretion from engineered macrophages for anti-tumor therapy" on the preprint platform bioRxiv on May 1, 2022...

Learn More
Previous Page

© 2023 RocRock Bio - Technology Co. , Ltd. All Rights Reserved. 苏ICP备2023037904号

‌

HTML Website Builder